Imugene Limited Receives $4.13 Million R&D Tax Refund from Australian Government

Australian immuno-oncology company, Imugene Limited (ASX: IMU) is developing a pipeline of mimotope-based B-cell immunotherapies against oncology targets that could replace or be used...

Lens through Imugene’s September 2019 Quarterly 4C Report

Biotechnology firm headquartered in Australia, Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology player that develops novel immunotherapies to treat and eradicate cancerous...

Imugene Commends City of Hope Researchers on Receiving US Department of Defense Grant

As per latest update from Imugene Limited (ASX: IMU), the prominent City of Hope researchers have received a Grant of USD 564,173 from the...

Imugene Released Program Update on Oncolytic Virus CF33’s Phase 1 Clinical Trial Plans

ASX-listed clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) has released an update on the preliminary clinical development plan for the intended exclusive license...

Imugene Hires Professor Yuman Fong to Lead Oncolytic Virotherapy Scientific Advisory Board

Australia-based clinical stage immuno-oncology firm, Imugene Limited (ASX: IMU) is involved in the development of various new and novel immunotherapies that attempt to stimulate...
5,709FansLike
2,650FollowersFollow
566SubscribersSubscribe

Latest News

Editorial